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Abstract
Rationale Nicotine, a dominant alkaloid found in tobacco, is
responsible for physical dependence, as well as addiction to
cigarette smoking; consequently, smoking cessation is a very
difficult process. Hepatic cytochrome P-450 2A6 (CYP2A6)
is involved in the 70–80 % of the initial metabolism of nico-
tine and its co-metabolites. As this metabolism is slowed by
inhibitors of CYP2A6, this kind of enzymatic inhibition has
been proposed as a novel target for smoking cessation.
Objectives Nicotine administered alone improved memory
acquisition and consolidation as well as exerted antidepressive
activity in animal models. These effects persist for 24 h.
However, they are completely extinguished 48 h after
administration.
Methods To investigate if the coumarins prolong the behav-
ioral effects of nicotine, the forced swimming test (FST)—
animal models of depression, and passive avoidance (PA)
test—memory and learning paradigm were used.
Results This study revealed that three CYP2A6 inhibitors:
two furanocoumarins, xanthotoxin (15 mg/kg) and bergapten
(25 mg/kg), and the simple coumarin umbelliferone
(25 mg/kg), prolonged the antidepressive and procognitive
effects of nicotine.
Conclusions These natural products may offer a new ap-
proach to the treatment of nicotinism as antidepressant and
memory improvement actions are one of the main factors of
nicotine dependence.
Keywords Coumarins . Nicotine .Memory . Depression .
Mice
Introduction
Nicotine, the main component of tobacco smoke, influences the
mood and emotional tension, as well as contributes to develop-
ment of physical and mental dependence. It is well documented
that nicotine exerts cognitive effects (Herman et al. 2010; Levin
2002; Levin et al. 2009), analgesia (Marubio et al. 1999), and
an influence on anxiety- (File et al. 2000) or depression-like
behaviors (Hayase 2011). The effects of nicotine have been
extensively investigated not only in humans but also in animals
and several cell systems (Biala et. al. 2014; Budzynska et al.
2012b; Dani and De Biasi 2001; Kruk-Slomka et al. 2012;
Malin 2001). Moreover, nicotine has strong addictive potential
resulting from activation of dopaminergic neurons in the
mesolimbic system, which are part of the reward system.
Thus, quitting smoking is very challenging and nicotine re-
placement therapy (NRT), with products that supply low doses
of nicotine, may be helpful in this process (Benowitz 2009).
Coumarins, based on the 2H-1-benzopyran-2-one scaf-
fold, are widely distributed in the plant kingdom and oc-
cur in the seeds, roots, and leaves of many plant species,
e.g., Apiaceae, Rutaceae, Fabaceae,Orchidaceae (O’Kennedy
and Thornes 1997 Coumarins possess a range of diverse phar-
macological properties. Plants containing coumarins are used
in traditional medicine all over the world for their antiprolifer-
ative, anticonvulsant, anxiolytic, and procognitive effects
(Abed et al. 2001; Budzynska et al. 2012a; Garcia-Argaez et al.
2000; Kawaii et al. 2001; Luszczki et al. 2007).
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Furthermore, several enzymes are involved in the metabo-
lism of nicotine. In humans, nicotine is metabolized to the
extent of 70–80 % to cotinine (5-oxo-nicotine) in a biphasic
process. The first step is catalyzed by hepatic cytochrome
P-450 2A6 (CYP2A6) to produce the nicotine iminium ion.
The next step is catalyzed by an aldehyde oxidase to produce
cotinine (Hukkanen et al. 2005; Murphy et al. 2005).
CYP2A6 also converts cotinine to trans-3-hydroxycotinine.
All three products, e.g., nicotine, cotinine, and trans-3-
hydroxycotinine, are glucuronidated and eliminated in the
urine (Yamanaka et al. 2004). Therefore, inhibition of the
hepatic metabolism of nicotine results in the slower elimina-
tion of nicotine in smokers (Sellers et al. 2003) and increases
the pharmacological effects of nicotine in animals (Alsharari
et al. 2014; Damaj et al. 2007).
In addition to nicotine, coumarins are important sub-
strates for human CYP2A6 and CYP2A13 (Raunio and
Rahnasto-Rilla 2012; Zhang et al. 2001). More signifi-
cantly, it was shown that these compounds inhibit
CYP2A5-mediated nicotine metabolism in vivo in the
mice (Damaj et al. 2007). CYP2A5 is a mouse cyto-
chrome P450 monooxygenase and it shows a high de-
gree of similarity with human CYP2A6 and CYP2A13
in protein sequence and substrate specificity (Su and
Ding 2004).
Xanthotoxin is an inhibitor of CYP2A5, monoamine oxi-
dase (MAO), acetylcholinesterase (AChE), and butyrylcholin-
esterase (BChE) (Skalicka-Wozniak et al. 2014). Bergapten, an
analog of xanthotoxin, is the most potent inhibitor of CYP3A4
(Ho et al. 2001). Furthermore, bergapten inhibits the activity of
BChE and AChE, which results in an increase of acetylcholine
(ACh) and butyrylcholine (BCh) in the brain (Senol et al.
2011), and bergapten inhibits the activity of MAO and shows
antidepressant effects (Huong et al. 1999). Umbelliferone also
has the ability to inhibit MAO (Seon et al. 2006). The data
suggest that this coumarin interacts with the benzodiazepine
binding site of the GABA-A receptor, which may indicate
anxiolytic activity (Singhuber et al. 2011). Nicotine metabo-
lism is slowed by hepatic enzyme inhibitors, and since
CYP2A6 is responsible for 70–80 % of the initial metabolism
of nicotine (Al Koudsi et al. 2010), CYP2A6 inhibition has
been proposed to be a novel target for smoking cessation.
Consequently, these natural products may offer a new ap-
proach in the treatment of nicotinism by prolonging the
effect of low levels of nicotine contained in NRT. The
potential problem of lack of a sustained effect of nicotine
with NRTs does not apply to the nicotine skin patch, which
delivers 24-h continuous dosing of nicotine. However, it
may be an issue with acute dosing forms, such as nicotine
gum or lozenge, which are typically underutilized by pa-
tients. Two furanocoumarins, xanthotoxin and bergapten,
and the simple coumarin, umbelliferone, were chosen for
the present study to investigate if they prolong the
behavioral effects of nicotine in animal models of depres-
sion, as well as memory and learning.
Animals and methods
Animals
The experiments were carried out on 2-month old, naïve male
Swiss albino mice (Farm of Laboratory Animals, Warsaw,
Poland). At the beginning of the experiments, they weighed
20–25 g. The mice were maintained under standard laboratory
conditions (12 h light/dark cycles, room temperature 21
±1°C). The mice were kept in colony cages (8–10 per cage)
with free access to food (Agropol, Poland) and tap water. After
1 week of adaptation to laboratory conditions, the animals
were randomly assigned to experimental group. Each group
consisted of 8–10 mice. All experiments were performed be-
tween 08:00 and 15:00 hour. Each mouse was used only once.
All experiments were conducted according to the National
Institute of Health Guidelines for the Care and Use of
Laboratory Animals (8th edition) and to the European
Community Council Directive for the Care and Use of
Laboratory Animals of 22 September 2010 (2010/63/EU)
and were approved by the local ethics committee (44/2015).
Drugs
The following compounds were tested: (–)-nicotine hydro-
gen tartrate (expressed as a salt, 0.1 and 0.2 mg/kg, Sigma–
Aldrich, St . Louis , MO, USA), xanthotoxin [8-
methoxyfuro[3,2-g]chromen-7-one] (15 mg/kg), bergapten
[5-methoxyfuro[3,2-g]chromen-7-one] (25 mg/kg), and
umbelliferone [7-hydroxychromen-2-one] (25 mg/kg).
Coumarins were isolated as described below. Nicotine
was dissolved in saline solution (0.9 % NaCl) and admin-
istered subcutaneously (s.c.) at a volume of 10 mL/kg. The
pH of the nicotine solution was adjusted to 7.0. Coumarins
were suspended in a 1 % solution of Tween 80 (Sigma-
Aldrich, St. Louis, MO, USA) dissolved in a saline solu-
tion and administered intraperitoneally (i.p.) at the volume
of 10 mL/kg. Fresh drug solutions were prepared on each
day of experimentation. Control groups received saline in-
jections of the same volume and through the same route of
administration.
Isolation of coumarins
Xanthotoxin was isolated from the dichloromethane ex-
tract of the fruits of Pastinaca sativa L. (Apiaceae)
(Skalicka-Wozniak et al. 2014), while bergapten and
umbelliferone were obtained from the dichloromethane
and methanol extracts of the fruits of Heracleum leskovii
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Grossch. (Apiaceae), respectively (Kielbus et al. 2013;
Skalicka-Wozniak et al. 2015). All plants were obtained
from the Medicinal Plant Garden, Department of
Pharmacognosy, Medical University of Lublin, Poland, in
the summer of 2010.
The extracts were separated using a high-performance
counter-current chromatograph Spectrum (Dynamic
Extractions, Slough, UK) and semipreparative coil with a
capacity of 137 mL was used. A solvent system composed
of heptane–ethyl acetate–methanol–water (1:1:1:1 v/v) was
used for the separation of xanthotoxin, (6:5:6:5) for
bergapten isolation, and (1:2:1:2) for umbelliferone. The
upper phase was used consistently as the stationary phase,
the rotation was set at 1600 rpm, and the mobile phase was
pumped into the column at a flow rate of 6.0 mL/min, and
the effluent from the coil was monitored at 254 nm.
Identification of the eluted compounds was confirmed by
HPLC-DAD and LC-TOF-MS analyses. The purity of iso-
lated compounds was higher than 98 %.
The passive avoidance task
The experimental apparatus consisted of two acrylic
compartments:
– Lighted compartment (10×13×15 cm); illuminated by a
fluorescent light (8 W).
– Darkened compartment (25×20×15 cm); equipped with
an electric floor Venault et al. 1986).
On the first day of the experiment (pretest), each mouse
was placed in the light chamber and allowed to move freely
in it for 30 s. After this time, the guillotine door between the
compartments was raised to allow the mice to enter the dark
chamber. When the experimental animal entered the dark
compartment, the guillotine door was closed and electric
foot-shock (0.15 mA) of 2-s duration was delivered to the
mouse through the grid floor. The latency time (TL1) was
recorded for entering the dark chamber. When the mouse
failed to enter the dark chamber within 300 s, it was placed
into this box. The guillotine doors were closed and an
electric foot-shock (0.15 mA) of 2-s duration was delivered
to the mouse through the grid floor. The TL1 was recorded
as 300 s.
Twenty-four hours later, the same mouse was placed indi-
vidually in the light chamber. After 30 s, the guillotine door
was raised to allow the mouse to enter the dark chamber. The
latency time (TL2) was recorded for reentering the dark cham-
ber. In this trial, no foot-shock was applied. When the mouse
failed to enter the dark chamber within 300 s, the TL2 was
recorded as 300 s (Allami et al. 2011; Borowicz et al. 1995;
Hiramatsu et al. 1998; Javadi-Paydar et al. 2012). The
experiment involves an examination of different memory
stages:
– Acquisition = formation of memory traces (the animal
received substances prior to the test)
– Consolidation (the animal received substances after
the test)
Forced swimming test
The forced swimming test (FST) is used for assessing an-
tidepressant activity (Lucki 1997). The experimental ani-
mals were immersed individually in clear glass cylinders
(diameter 10 cm; height 25 cm) containing 10 cm of water
(to prevent their tails from touching the bottom) at a tem-
perature of 23–25 °C. The animals were allowed to swim
without any possibility of escape. After 2 min of observing
the mouse in the water, the test was started. Immobility was
manually recorded over the 4-min testing period. Animal
mobility is limited apart from the movements necessary to
keep the head above the water. After 6 min of test session,
the animal was removed, dried, and returned to their cage.
Antidepressant activity was characterized by a decrease in
the immobility time.
Locomotor activity
The locomotor activity of mice was measured using
photoresistor actimeters (circular cage, diameter 25 cm, two
light beams). The animals were placed individually in an
actimeter for 60 min. When mice crossed the light beams, it
was recorded as the locomotor activity. Locomotor activity of
mice was measured with photoresistor actimeters (circular
cages, diameter 25 cm, two light beams).
Treatment
The doses of the coumarins and nicotine as well as time of the
experiments were chosen based on literature data (Alsharari
et al. 2014; Bagdas et al. 2014), a recently published article
from this laboratory (Budzynska et al. 2013), and
preliminary studies. To determine the effects of nicotine
(0.1 mg/kg), xanthotoxin (15 mg/kg), bergapten (25 mg/kg),
and umbelliferone (25 mg/kg) on memory acquisition, trial
drugs were administered 30 min before the first trial (TL1)
and animals were retested 24 h after the injection (TL 2)
(Diagram 1a). To determine the effects of drugs on memory
consolidation trial, the compounds were administered imme-
diately after the first trial (TL1) and animals were retested 24 h
after the injection (TL 2) (Diagram 2a). Moreover, to assess
the effects of nicotine (0.2 mg/kg), xanthotoxin (15 mg/kg),
bergapten (25 mg/kg), umbelliferone (25 mg/kg), or saline
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injection on depressive-like behavior, drugs were adminis-
tered 30 min before the FST (Diagram 3a) (Fig. 1).
To determine if coumarins prolong the behavioral effects of
nicotine in animal models of depression, as well as memory,
and learning the animals were allocated to the following drug
groups: nicotine (0.1 or 0.2 mg/kg, s.c.) + saline, saline +
xanthotoxin (15 mg/kg, i.p.), saline+bergapten (25 mg/kg,
i.p.), or saline+umbelliferone (25 mg/kg, i.p.), and nicotine
(0.1 or 0.2 mg/kg, s.c.), coadministered with xanthotoxin
(15 mg/kg, i.p.), bergapten (25 mg/kg, i.p.), or umbelliferone
(25 mg/kg, i.p.). The TL1 trial in the PA tests was performed
30 min after drug administration (memory acquisition) or im-
mediately before drug administration (memory consolidation)
and then the TL2 trial was performed 48 h later (Diagrams 1b
and 2b). The FST was made 48 h after drugs administration
(Diagram 3b).
Locomotor activity
In order to measure locomotor effects of nicotine (0.1 and
0.2 mg/kg), xanthotoxin (15 mg/kg), bergapten (25 mg/kg),
or umbelliferone (25 mg/kg), animals were injected with
drugs and immediately placed in the activity chamber.
Locomotor activity, i.e., the number of photocell beam breaks
was automatically recorded.
































Diagram 1 Diagram shows the schedule of administration of coumarins
(i.p.) and nicotine (s.c.) in the PA paradigms. The tests were performed
30 min after drug administration (TL1) and 24 h later (TL2) to observe
acute effects of coumarins and nicotine on memory acquisition processes
(a) or 30 min after drug administration (TL1) and then 48 h later (TL2) to
observe if coumarins prolonged effects of nicotine onmemory acquisition
processes (b)
immediatelly     
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Diagram 2 Diagram shows the schedule of administration of coumarins
(i.p.) and nicotine (s.c.) in the PA paradigms. To observe acute effects of
coumarins and nicotine on memory consolidation processes, a the drugs
were administered immediately after TL1 trial and 24 h later, the TL2 trial
was performed. In turn, to observe if coumarins prolonged effects of
nicotine on memory consolidation processes, b the drugs were
administered immediately after TL1 trial and 48 h hours later, the TL 2
trial was performed
2292 Psychopharmacology (2016) 233:2289–2300
Statistical analysis
Data were analyzed using two-tailed ANOVA test with post
hoc Tukey’s test. All data are shown as means (±SEM). The
results of p<0.05 were considered as statistically significant.
For the memory-related behaviors, changes in the PA per-
formance were expressed as the difference between the reten-
tion and training latencies and were taken as an index of la-
tency (IL). IL was calculated for each animal and reported as
the ratio:
IL=TL2-TL1/TL1
TL1—the time taken to enter the dark compartment during
the training
TL2—the time taken to reenter the dark compartment dur-
ing the retention (Budzynska et al. 2015; Chimakurthy and
Talasila 2010).
Results
Single injection of nicotine, xanthotoxin, bergapten,
and umbelliferone affects memory-related processes 24 h
after drug administration in the PA test in mice
One-way ANOVA revealed that, at the acquisition trial, the
acute administration of nicotine (0.1 mg/kg), xanthotoxin
(15 mg/kg), bergapten (25 mg/kg), and umbelliferone
(25 mg/kg) significantly changed IL values [F(4,43)=4.56;
p=0.0040]. The post hoc Tukey’s test showed that nicotine
(p<0.05), xanthotoxin (p<0.01), bergapten (p<0.001), and
umbelliferone (p<0.01) significantly increased IL as com-
pared to the saline-treated mice, indicating improvement of
memory and learning processes as measured 24 h after their
administration (Fig. 1a).
One-way ANOVA revealed that, at the consolidation trial,
the acute administration of nicotine (0.1 mg/kg), xanthotoxin
(15 mg/kg), bergapten (25 mg/kg), and umbelliferone
(25 mg/kg) significantly changed IL values [F(4,41)=2.84;
p=0.0378]. The post hoc Tukey’s test showed that nicotine
(p<0.05), xanthotoxin (p<0.05), bergapten (p<0.01), and
umbelliferone (p<0.05) significantly increased IL as com-
pared to the saline-treated mice, indicating improvement of
memory and learning processes (Fig. 1b).
Effects of single injection of nicotine, xanthotoxin,
bergapten, and umbelliferone on depression-like
behaviors 24 h after drug administration in the FST
in mice
Figure 2 shows the effect of nicotine (0.2 mg/kg), xanthotoxin
(15 mg/kg), bergapten (25 mg/kg), and umbelliferone
(25 mg/kg) on depression-like behaviors in the FST (one-
way ANOVA: F(4,47) = 7.18, p = 0.0002). A post hoc
Tukey’s analysis showed significant changes only after nico-
tine administration at the doses of 0.2 mg/kg in the immobility
time as compared with the saline-treated mice (p<0.01) as
measured 24 h after its administration (Fig. 2).
Single injection of xanthotoxin, bergapten,
and umbelliferone affects memory-related processes
induced by nicotine 48 h after drug administration
in the PA test in mice
Figure 3a (a) indicates the effects of the injection of
xanthotoxin (15 mg/kg) and nicotine (0.1 mg/kg, s.c.) alone
or in combination on memory acquisition 48 h after drug
administration in the PA task (two-wayANOVA: pretreatment
[F(1,28) = 10.91, p= 0.0026], interactions [F(1,28) = 6.20,







































Diagram 3 Diagram shows the schedule of administration of coumarins
(i.p.) and nicotine (s.c.) in the FST. The test was performed 30 min after
drug administration to observe acute effects of coumarins and nicotine (a)
or 48 h after drug administration to observe if coumarins prolonged the
effects of nicotine (b)
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p=0.0934]). In the xanthotoxin and nicotine-treated groups,
there were no significant changes in the IL value as compared
with the saline-treated mice (p> 0.05), indicating that the
procognitive effects of these compounds did not persist 48 h
after their administration. However, the post hoc Tukey’s test
revealed a statistically significant improvement in cognitive
processes in the animals administered with xanthotoxin
(15 mg/kg) and nicotine (0.1 mg/kg, s.c.), as compared with
the mice treated only with xanthotoxin or nicotine (p<0.05,
p<0.01, respectively).
For memory consolidation during the retention trial, two-
way ANOVA revealed a statistically significant effect caused
by the administration of xanthotoxin (15 mg/kg) and nicotine
(0.1 mg/kg) (pretreatment [F(1,28)=5.71, p=0.0239], treat-
ment [F(1,28) = 24.39, p< 0.0001], and interaction effects
[F(1,28) = 11.24, p= 0.0023]). The post hoc Tukey’s test
showed that neither xanthotoxin nor nicotine induced signifi-
cant changes in the IL value as compared with the saline-
treated mice (p>0.05). However, the post hoc Tukey’s test
revealed a statistically significant effect in memory and learn-
ing processes in the animals administered with xanthotoxin
(15 mg/kg) and nicotine (0.1 mg/kg) in combination as com-
pared with mice treated with only xanthotoxin or nicotine
(p<0.001) 48 h after injection (Fig. 3b (a)).
Figure 3a (b) indicates the effects of the injection of
bergapten (25 mg/kg) and nicotine (0.1 mg/kg, s.c.), alone
or in combination on memory acquisition 48 h after drug
administration in the PA task (two-way ANOVA: interactions
[F(1,25) = 4.41, p = 0.046] without pretreatment [F(1,
25)=2.31, p=0.1410] and treatment effects [F(1,25)=0.22,
p=0.6458]). In the bergapten- and nicotine-treated groups,
there were no significant changes in the IL value as compared
with the saline-treated mice (p>0.05), indicating that these
drugs did not influence the acquisition of memory and learn-
ing 48 h after their injection. However, the post hoc Tukey’s
test revealed a statistically significant improvement in cogni-
tive processes in the animals administered with bergapten
(25 mg/kg) and nicotine (0.1 mg/kg) as compared with the
nicotine-treated mice (p<0.05).
For memory consolidation during the retention trial, two-
way ANOVA did not reveal any statistically significant effect
caused by administration of bergapten and nicotine (pretreat-
ment [F(1,30)= 0.33, p=0.5706], treatment [F(1,30)= 2.57,









































































































































Fig. 1 Effects of nicotine (0.1 mg/kg), xanthotoxin (15 mg/kg),
bergapten (25 mg/kg), umbelliferone (25 mg/kg), or saline injection on
memory acquisition trial (a) and consolidation trial (b) using the PA test
in mice. Drugs were administered 30 min before the first trial (a) or
immediately after the first trial (b), and animals were retested 24 h after
the injection; n = 8–10; the means ± SEM; *p < 0.05; **p < 0.01

































































Fig. 2 Effects of nicotine (0.2 mg/kg), xanthotoxin (15 mg/kg),
bergapten (25 mg/kg), and umbelliferone (25 mg/kg) or saline injection
on the total duration of immobility in the FST in mice. Drugs or saline
were administered 30 min before the test and animals were retested 24 h
after the injection; n= 8–10; the means ± SEM; *p < 005 vs. saline control
group; Tukey’s test









































































































































































































































































































































































































































Fig. 3 Effects of the injection of coumarins on nicotine-induced memory
acquisition trial (a) and consolidation trial (b) after extinction using the
PA test in mice. Xanthotoxin (15 mg/kg; a), bergapten (25 mg/kg; b), and
umbelliferone (25 mg/kg; c), saline and/or nicotine (0.1 mg/kg) were
administered 30 min before the first trial (a) or immediately after the
first trial (b), and animals were retested 48 h after the last injection;
n = 8–10; the means ± SEM; *p < 0.05; **p < 0.01 ***p < 0.001 vs.
nicotine-treated control group, #p< 0.05, ###p < 0.001 vs. xanthotoxin-
or umbelliferone-treated control group; Tukey’s test
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9324]). The post hoc Tukey’s test showed that neither
bergapten nor nicotine induced significant changes in the IL
value as compared with the saline-treated mice (p>0.05).
Also, the post hoc Tukey’s test did not reveal any statistically
significant effect in memory and learning processes in the
animals administered with bergapten (15 mg/kg) and nicotine
(0.1 mg/kg) 48 h after injection (Fig. 3b (b)).
Figure 3a (c) indicates the effects of the injection of
umbelliferone (25 mg/kg) and nicotine (0.1 mg/kg, s.c.), alone
or in combination, on memory acquisition 48 h after drug
administration in the PA task (two-wayANOVA: pretreatment
[F(1,27) = 4.43, p = 0.0008], treatment [F(1,27) = 6.81,
p = 0.0146], and interaction effects [F(1,27) = 6.12,
p = 0.0190]). In the umbelliferone- and nicotine-treated
groups, there were no significant changes in the IL value as
compared with the saline-treated mice (p>0.05), indicating
that these drugs did not influence the acquisition of memory
and learning 48 h after injection. On the other hand, the post
hoc Tukey’s test revealed a statistically significant improve-
ment in the cognitive processes in those animals administered
with umbelliferone (25 mg/kg) and nicotine (0.1 mg/kg, s.c.),
as compared with the nicotine-treated mice (p<0.001) and
umbelliferone-treated groups (p<0.01).
For memory consolidation during the retention trial, two-
way ANOVA did not reveal any statistically significant effect
caused by the administration of umbelliferone and nicotine
(treatment [F(1,25)=5.45, p=0.0278], without pretreatment
[F(1,25) = 2.62, p= 0.1182], and interaction effects [F(1,
25)= 0.01, p=0.9370]). The post hoc Tukey’s test showed
that neither umbelliferone nor nicotine induced significant
changes in the IL value as compared with the saline-treated
mice (p>0.05). Also, the post hoc Tukey’s test did not reveal
any statistically significant effect in memory and learning pro-
cesses in the animals administered with umbelliferone
(15 mg/kg) and nicotine (0.1 mg/kg) 48 h after injection
(Fig. 3b (c)).
Effects of xanthotoxin, bergapten, and umbelliferone
on depression-like behaviors induced by nicotine
in the FST 48 h after drug administration
In the group injected with xanthotoxin and nicotine, two-way
ANOVA revealed a significant treatment effect [F(1,
28) = 9.14, p=0.0053], without interaction [F(1,28) = 2.11,
p = 0.1579] and pretreatment effects [F(1,28) = 2.08,
p=0.1606]. In the xanthotoxin- and nicotine-treated groups,
there were no significant changes in the immobility time as
compared with the saline-treated mice (p>0.05), indicating
that these drugs did not influence the depression-like behavior
48 h after injection. Coadministration of xanthotoxin
(15 mg/kg) and nicotine (0.2 mg/kg) decreased the immobility
time in the FST vs. the xanthotoxin- or nicotine-treated mice

























































































































































































































Fig. 4 Effects of the injection of xanthotoxin (15 mg/kg; a), bergapten
(25 mg/kg; b), and umbelliferone (25 mg/kg; c) on nicotine-induced
(0.2 mg/kg) immobility time after extinction using the FST in mice.
The test was performed 48 h after drug administration. Data represent
the means ± SEM; n = 8–10; *p <0.05 vs. nicotine-treated control group;
#p < 0.05, ###p < 0.001; vs. the selected coumarin (xanthotoxin,
bergapten, or umbelliferone)-treated control group; Tukey’s test
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In the group injected with bergapten and nicotine, two-way
ANOVA revealed a significant treatment effect [F(1,
32) = 8.47, p = 0.0065] and pretreatment effect [F(1,
32) = 7.41, p=0.0104] without interactions [F(1,32) = 4.00,
p=0.0539]. In the bergapten- and nicotine-treated groups,
there were no significant changes in the immobility time as
compared with the saline-treated mice (p>0.05), indicating
that these drugs did not influence the depression-like behavior
48 h after injection. Coadministration of bergapten (25 mg/kg)
and nicotine (0.2 mg/kg) decreased the immobility time in the
FST vs. the bergapten- or nicotine-treated mice (p<0.05, post
hoc Tukey’s test) (Fig. 3b).
In the group injected with umbelliferone and nicotine, two-
way ANOVA revealed a significant treatment [F(1,
27) = 24.94, p < 0.0001], pretreatment [F(1,27) = 5.98,
p = 0.0213], and interaction effects [F(1,27) = 4.76,
p=0.0380]. In the umbelliferone- and nicotine-treated groups,
there were no significant changes in the immobility time as
compared with the saline-treated mice (p>0.05), indicating
that these drugs did not influence the depression-like behavior
48 h after injection. Coadministration of umbelliferone and
nicotine decreased the immobility time in the FST vs. the
umbelliferone- or nicotine-treated mice (p<0.001, p<0.05,
respectively, post hoc Tukey’s test) (Fig. 4c).
Effects of coumarins and nicotine on locomotor activity
Neither coumarins nor nicotine (0.1 and 0.2 mg/kg) adminis-
tered separately influenced locomotor activity of mice 60 min
after administration (mean photocell beam-break: saline
724.61±52.75; nicotine (0.1 mg/kg) 623.56±117.5; nicotine
(0.2 mg/kg) 651.66 ± 48.890; xanthotoxin 608.45 ± 29.72;
bergapten 704.42 ± 76.28; umbelliferone 687.51 ± 49.48;
one-way ANOVA F(5,52)=0.5266, p=0.0113).
Discussion
Nicotine, the principal alkaloid of tobacco, induces diverse
behavioral effects, including the procognitive (Kruk-Slomka
et al. 2012; Levin et al. 2009), anxiogenic (Budzynska et al.
2013; File et al. 2000), analgesic (Marubio et al. 1999), or
antidepressive activity (Hayase 2011). Additionally, smoking
cessation causes somatic and affective (motivational) symp-
toms, which are observed within a few hours following
discontinuation of nicotine intake. During nicotine with-
drawal, depression is accompanied by cognitive deficits
and anxiety (Hughes 2007; Stolerman and Shoaib
1991). These studies were undertaken to examine whether
three natural coumarins could modulate nicotine-induced be-
havioral effects (memory and depression) in mice. Nicotine
improved memory acquisition and consolidation measured in
the PA test 24 h after drug administration (Budzynska et al.
2015). Moreover, this alkaloid showed antidepressive activity
in the FST 30 min after injection and this effect persisted 24 h.
Our present studies revealed that xanthotoxin, bergapten, and
umbelliferone also exerted procognitive effects in PA test;
whereas, they did not influence immobility time in the FST
measured 24 h after drug injections. However, effects of cou-
marins and nicotine were completely extinguished 48 h after
drug administration. Thus, for the first time, it was revealed
that the two furanocoumarins, xanthotoxin, and bergapten, as
well as the simple coumarin, umbelliferone, prolonged the
antidepressive, as well as the procognitive effects of nicotine,
and these results are not modulated by the influence of these
compounds on locomotor activity.
A potential limitation of this study was that the plasma
level of nicotine after coadministration of this alkaloid with
coumarins was not measured, thus we cannot exclude that
interactions between nicotine and coumarins may be due to
pharmacodynamic interactions, not pharmacokinetic ones.
However, it was revealed earlier that xanthotoxin at the dose
of 15 mg/kg increased the nicotine plasma level in vivo in
mice (Alsharari et al. 2014). Moreover, it was shown that
xanthotoxin inhibited human CYP2A6 and CYP2A3, through
different mechanisms and in a time-dependent manner (Visoni
et al. 2008). It was also demonstrated that xanthotoxin inhibits
cytochrome CYP2A5 and CYP2A3 in mice and rats. Human
CYP2A6 is present in the liver and in the nasal mucosa of the
esophagus and is involved in the biotransformation of nicotine
(Visoni et al. 2008). Thus, it is concluded that the metabolism
of nicotine in the mouse is very similar to that occurring in
human. It was also shown that xanthotoxin significantly re-
duced the metabolic elimination of nicotine in vivo (Raunio
et al. 2008; Sellers et al. 2003), as well as inhibited the
CYP2A5-mediated metabolism of nicotine in liver micro-
somes (Damaj et al. 2007).
The present experiments follow the previous studies show-
ing that pretreatment with xanthotoxin prolongs the duration
of nicotine-induced antinociception and hypothermia and that
this effect was associated with a prolongation of nicotine plas-
ma levels in mice (Alsharari et al. 2014). The present results
extend the findings of Bagdas et al. (2014) demonstrating
that administration of xanthotoxin increases and prolongs
nicotine levels thereby enhancing nicotine dependence-
related behaviors in mice, indicating the relationship be-
tween the metabolism of nicotine and the nicotine addic-
tion state in animal models (Bagdas et al. 2014). Other
furanocoumarins, such as bergapten, imperatorin, and
isopimpinellin, are potent inhibitors of coumarin 7-
hydroxylation in mice (Chang and Waxman 1996). It was
also revealed, in a study of CYP3A4 inhibition by furano-
coumarins contained in grapefruit juice, that bergapten is
probably the most potent inhibitor of CYP3A4, which is
regarded as the major drug-metabolizing oxidase in human
liver (Cuciureanu et al. 2010).
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The present results demonstrated that administration of
xanthotoxin, bergapten, and umbelliferone significantly
prolonged nicotine-induced antidepressive effects, at a similar
level. Differences between the effects of the coumarins on
memory processes induced by nicotine were observed.
Xanthotoxin prolonged the duration of nicotine-induced acqui-
sition and consolidation of memory, whereas bergapten and
umbelliferone influenced only memory acquisition in the PA
test. These results are in agreement with previous studies from
this laboratory which showed that coadministration of inactive
doses of nicotine (0.05 mg/kg s.c.) and imperatorin (1 mg/kg,
i.p.) provided a statistically significant improvement in acqui-
sition of memory and learning processes and did not affect
consolidation processes (Budzynska et al. 2013).
The previous study revealed that nicotine improved both
memory acquisition and consolidation processes. It is
established that the distinct memory stages, acquisition and
consolidation are temporally and molecularly different. In
these processes, mainly cholinergic, dopaminergic, and gluta-
matergic neurotransmissions participate, and GABA, nor-
adrenalin, adrenaline, and serotonin are involved in memory
modulation (Abel and Lattal 2001; Levin and Rezvani 2007).
More recent experiments have revealed that ACh is involved
mainly in the initial acquisition processes. Thus, inhibition of
the muscarinic acetylcholine receptors significantly disturbs
memory acquisition (Gil-Bea et al. 2011; Robinson et al.
2011). Additionally, it was shown that dopamine is more com-
mitted in the consolidation of memory processes lasting from
minutes to days (Bethus et al. 2010). Nicotine, as a cholinergic
receptor agonist, is known to activate the cholinergic system,
and, as a drug of abuse, it also directly activates dopaminergic
pathways projecting from the ventral tegmental area to the
nucleus accumbens and the hippocampus (Zaniewska et al.
2009). Thus, the differences observed in the effects onmemory
processes among xanthotoxin, bergapten, and umbelliferone
may be due to the more pronounced influence of nicotine on
cholinergic transmission which were observed 48 h after drug
administration, rather than on dopaminergic pathways.
The observed results may also indicate that C-8 substituted
coumarins (e.g., xanthotoxin) possess stronger pharmacolog-
ical activity than those with the C-5 position of the psoralen
ring substituted (e.g., bergapten). This hypothesis is supported
by the previous study which clearly demonstrated that impera-
torin and xanthotoxin, both of which are substituted at the C-8
position of the psoralen ring, may serve as potential com-
pounds for further development against tonic–clonic seizures.
Similarly, the lack of anticonvulsant activity shown by
bergapten and oxypeucedanin, which are C-5 substituted com-
pounds, confirmed that the regio-oxygenation plays an impor-
tant role in the pharmacological evaluation of natural couma-
rins in preclinical studies (Luszczki et al. 2010). Thus, it can
be hypothesized that some modifications and/or manipula-
tions of the chemical structures of both compounds at the
C-8 position of the psoralen ring might be profitable from a
preclinical development perspective. Since it was shown that
the CYP2A6 gene is polymorphic, it is suggested that inhibi-
tion of this enzyme will have no negative effects.
Furthermore, since not many drugs, other than nicotine, are
metabolized by this enzyme, the probability of unexpected
interactions would appear to be minimal (Raunio et al. 2001).
Overall, the present study showed that furanocoumarins
xanthotoxin and bergapten and the simple coumarin
umbelliferone prolonged the behavioral effects of nicotine.
The results suggest that these metabolites, which are readily
available, exert a modulating effect on the metabolism of nic-
otine and should be further explored as a novel
pharmacotherapeutic approach for the treatment of nicotinism.
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